Key findings for IMM development:

See Table 8.16 for comparison between treatments identified in Chapter 6 and new treatments identified from the interview process for exposure to new risks.

Table 8.16 Treatments for Change of Consortium Members / Change to Public Partner's Agency Authority.

Treatments Identified in Previous
Chapters

New Treatments Identified From
Interviews

Exposure to new risks

- Update / report on risk registers, business continuity plans, issue logs etc (Chapter 4 - 4.2, 4.3, Chapter 5 - 5.2, Chapter 6 - 6.4)

- Distillation and documentation of key commercial and project learning (PT03, RK05, RK06)

- Probity checks (PT11, PT14)

- Succession planning (RK05)

- Stakeholder management planning (RK07)

- Communication planning (RK07)

- Issues management planning (RK07)

More Information